99 related articles for article (PubMed ID: 4038385)
1. Metoclopramide kinetics at high-dose infusion rates for prevention of cisplatin-induced emesis.
Saller R; Hellenbrecht D; Briemann L; Hellstern A; Hess H; Mitrou P; Hodgson M; Achtert G; Brockmann P; Hausleiter HJ
Clin Pharmacol Ther; 1985 Jan; 37(1):43-7. PubMed ID: 4038385
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis.
Ell C; Braun J; König HJ; Domschke S; Domschke W
Klin Wochenschr; 1985 Jun; 63(12):572-4. PubMed ID: 3928960
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
[TBL] [Abstract][Full Text] [Related]
4. Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.
Warrington PS; Allan SG; Cornbleet MA; MacPherson JS; Smyth JF; Leonard RC
Br Med J (Clin Res Ed); 1986 Nov; 293(6558):1334-7. PubMed ID: 3790968
[TBL] [Abstract][Full Text] [Related]
5. Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis.
Agostinucci WA; Gannon RH; Golub GR; Martin RS; Schauer PK; Dinonno EB
Clin Pharm; 1988 Jun; 7(6):454-7. PubMed ID: 3402181
[TBL] [Abstract][Full Text] [Related]
6. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
[TBL] [Abstract][Full Text] [Related]
7. The effect of administration rate on cisplatin-induced emesis.
Jordan NS; Schauer PK; Schauer A; Nightingale C; Golub G; Martin RS; Williams HM
J Clin Oncol; 1985 Apr; 3(4):559-61. PubMed ID: 3884747
[TBL] [Abstract][Full Text] [Related]
8. High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis.
Saller R; Hellenbrecht D
Eur J Cancer Clin Oncol; 1986 Oct; 22(10):1199-203. PubMed ID: 3545851
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy.
McDermed JE; Cohen JL; Joseph C; Strum SB
J Clin Oncol; 1985 Oct; 3(10):1400-8. PubMed ID: 3900303
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion of metoclopramide for prevention of chemotherapy-induced emesis.
Agostinucci WA; Gannon RH; Schauer PK; Walters JK
Clin Pharm; 1986 Feb; 5(2):150-3. PubMed ID: 3956123
[No Abstract] [Full Text] [Related]
11. Optimizing metoclopramide control of cisplatin-induced emesis.
Meyer BR; Lewin M; Drayer DE; Pasmantier M; Lonski L; Reidenberg MM
Ann Intern Med; 1984 Mar; 100(3):393-5. PubMed ID: 6538075
[TBL] [Abstract][Full Text] [Related]
12. Improved benefit/risk ratio of higher-dose metoclopramide therapy during cisplatin-induced emesis.
Saller R; Hellenbrecht D; Hellstern A; Hess H
Eur J Clin Pharmacol; 1985; 29(3):311-2. PubMed ID: 4076327
[TBL] [Abstract][Full Text] [Related]
13. The relationship between steady state metoclopramide levels and control of emesis during treatment with cis-platinum.
Kerr DJ; Graham J; Blackie RG; McGovern E; Kelman AW; Cunningham D; Kaye SB
Br J Clin Pharmacol; 1985 Oct; 20(4):426-7. PubMed ID: 4074612
[No Abstract] [Full Text] [Related]
14. Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis.
Hellenbrecht D; Saller R
Arzneimittelforschung; 1986 Dec; 36(12):1845-9. PubMed ID: 3566848
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing two short courses of moderate-dose metoclopramide for moderate-dose cisplatin-induced emesis.
Pollera CF; Conti EM; De Nigris A; Calabresi F
Oncology; 1987; 44(2):73-7. PubMed ID: 3554084
[TBL] [Abstract][Full Text] [Related]
16. [Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach].
Brechot JM; Dupeyron JP; Guyon F; Delfour C; Delattre C; Lebeau B; Rochemaure J
Presse Med; 1988 Jun; 17(22):1147-9. PubMed ID: 2840652
[TBL] [Abstract][Full Text] [Related]
17. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
[TBL] [Abstract][Full Text] [Related]
18. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting.
Taylor WB; Proctor SJ; Bateman DN
Br J Clin Pharmacol; 1984 Nov; 18(5):679-84. PubMed ID: 6508977
[TBL] [Abstract][Full Text] [Related]
20. [Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis].
Sawamura N; Funaki Y; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Yoshioka S; Sakurai M; Eguchi K
Gan To Kagaku Ryoho; 1985 Apr; 12(4):943-6. PubMed ID: 3885865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
